A potential impact of Helicobacter pylori ‐related sarcopenia on severity of portal hypertension-Reference-Cited by-同舟云学术

A potential impact of Helicobacter pylori ‐related sarcopenia on severity of portal hypertension

Published:2021-01-09 Issue:5 Volume:41 Page:1168-1169
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver International

Author:

Kountouras Jannis¹^ORCID,Papaefthymiou Apostolis¹²³^ORCID,Polyzos Stergios A³^ORCID,Doulberis Michael¹³⁴^ORCID

Affiliation:

1. Department of Medicine Second Medical Clinic,Aristotle University of Thessaloniki Ippokration Hospital Thessaloniki Greece

2. Department of Gastroenterology University Hospital of Larisa Larisa Greece

3. First Laboratory of Pharmacology School of Medicine Aristotle University of Thessaloniki Thessaloniki Greece

4. Division of Gastroenterology and Hepatology Medical University Department Kantonsspital Aarau Aarau Switzerland

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.14777

Reference5 articles.

1. Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension;Paternostro R;Liver Int,2020

2. A possible impact of common worldwide environmental agents on the prognosis of critically ill cirrhotic patients

3. Helicobacter pylori infection in patients with liver cirrhosis: prevalence and association with portal hypertensive gastropathy;Sathar SA;Ann Gastroenterol,2014

4. Association between Sarcopenia and Metabolic Syndrome in Middle-Aged and Older Non-Obese Adults: A Systematic Review and Meta-Analysis

5. Elderly women who received Helicobacter pylori-eradicating therapy have reduced risk of low skeletal muscle mass

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B;Journal of Viral Hepatitis;2023-05-03

2. Letter: higher severe outcomes among Helicobacter pylori‐related lean patients with non‐alcoholic fatty liver disease and metabolic comorbidities;Alimentary Pharmacology & Therapeutics;2023-04-24